only shed light on its etiology, pathology, and diagnosis, it will also provide useful insight into treating it.
HBs occur sporadically or in von Hippel-Lindau (VHL) disease.
Although there are vast differences between the two subtypes of HBs in terms of genetics, age of onset, clinic recurrence, and other involved organs, they share identical histopathology. Germline mutations or aberrations in the VHL gene have been identified as the root cause of VHL disease. It has been estimated that only approximately 4% of VHL gene carriers are asymptomatic (Beitner, Winship, & Drummond, 2011; Catapano et al., 2005) , with CNS-HBs occurring in up to 60-80% of VHL patients (Maher et al., 1990; Richard et al., 2000; Wanebo, Lonser, Glenn, & Oldfield, 2003) . It is also thought that there were 4-25% of seemingly sporadic HBs are VHL somatic mutations (Fukino, Teramoto, Adachi, Takahashi, & Emi, 2000; Hes et al., 2000; Neumann et al., 1989) . These observations indicate that a dysfunctional or absent VHL protein (pVHL) could be involved in the tumorigenesis of HB, but it alone might not be enough to induce the lesions (Ma et al., 2011; Nordstrom-O'Brien et al., 2010) . Additional genetic variations that may contribute to the tumorigenesis of HB have not yet been identified (Nordstrom-O'Brien et al., 2010; Sims, 2001 ).
Furthermore, identified mutations span the entire VHL gene and occur in nearly every codon (Nordstrom-O'Brien et al., 2010) .
Dysfunctional or absent pVHL has organ-specific expression and age-dependent penetrance. Moreover, different types of VHL mutations could also influence tumorigenesis. For example, VHL deletions and protein truncating mutations appear to confer a higher risk of CNS-HBs than missense mutations (Cybulski et al., 2002; Franke et al., 2009; Maher et al., 1996; Maranchie et al., 2004) . Previous studies have indicated the importance of different pathways in the development of HB neoplasms as well as the existence of additional unknown genetic alterations that might drive disease progression (Dulaimi et al., 2004) . In this study, we performed a whole exome sequencing to explore the possible genetic variations that may contribute to the tumorigenesis of HBs.
| MATERIALS AND METHODS

| Study participants
Eleven HB samples and the corresponding peripheral blood samples (including six sporadic HBs and five familial HBs, respectively) were selected randomly from the sample bank in the Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University. These patients underwent resection of CNS-HBs between November 2008 and June 2015 at our hospital. All the specimens were ultimately diagnosed by experienced neuropathologists. The five patients with familial HBs were from three families. All of the familial HB patients had a family history of HBs, and VHL mutations were identified in genetic testing. All the sporadic HB patients had no family history of HB, showed no clinical signs of VHL HBs, and did not show any VHL mutation. This research was approved by the institutional review board of Huashan Hospital (KY2009-313). Informed consent was obtained from all patients.
| Extraction of DNA
In this study, the sample detection included concentration, sample integrity, and purification of the extracted DNA. Concentration was detected using a fluorometer or a Microplate Reader (Qubit Fluorometer, Invitrogen, Carlsbad, CA). Sample integrity and purification were detected by Agarose Gel Electrophoresis (concentration of agarose gel: 1%, voltage: 150 V, electrophoresis time: 40 min). Library construction followed the standard commercial guidelines. Briefly, 1-2µg of genomic DNA was randomly fragmented using Covaris AFA process to an average size of 250-300 bp. Fragments were end repaired, and an extra A base was added to the 3′ end. Illumina adaptors were ligated to the fragments, and proper cycles of polymerase chain reaction (PCR) amplification were applied to each sample after ligation. DNA was quantified using either Agilent 2100 Bioanalyzer or the Qubit fluorometer (Invitrogen, Carlsbad, CA). We used the required amount of pre-capture library for each capture reaction. Agilent SureSelect, NimbleGen SeqCap EZ Hybridization and Wash kits (Roche, Basel, Switzerland) were used for whole-exome capture following the standard manufacturer's protocol.
| Exome capture and sequencing and bioinformatics analysis
Genomic DNA was extracted from the tumor and blood of each of the 11 patients, and then it was fragmented randomly. After electrophoresis, DNA fragments of the desired length were gel purified. Adapter ligation and DNA cluster preparation were performed and the samples were subjected to Solexa sequencing (Mardis, 2008; Wang et al., 2008; Wheeler et al., 2008) . WES was performed using the Complete Genomics (CG) platform, which utilizes two proprietary technologies, DNA nanoball (DNB) sequencing and combinatorial probe-anchor ligation (cPAL). The results showed a high concordance with the Illumina platform and a high sensitivity (Lam et al., 2012; Porreca, 2010) . To minimize the likelihood of systematic bias in the sampling, two paired-end libraries with an insertion size of 500 bp were prepared for all the samples and then they subjected to whole exome sequencing. This resulted in at least 30-fold haploid coverage for each sample. Raw image files were processed using the Illumina pipeline for base calling with default parameters, and the whole exome sequences of each individual patient were generated as 90-bp-paired-end reads.
We used the Burrows-Wheeler Aligner program (Li & Durbin, 2009 ) to map the raw sequencing data for each individual to the human reference genome (build hg19). We then used Picard to sort and mark duplicated reads. Gene mutations or alterations in peripheral blood were considered to be nonspecific genetic variations and were excluded from the final analyses. The SNVs were detected by VarScan (Koboldt et al., 2009) . p-values were calculated by Fisher's exact test on the read counts, using reference and variant allele (Koboldt et al., 2009) . The CNVs of the normal samples and the tumor samples were detected by in-house pipeline CNV-Detection (BGI-Tech, Shenzhen, Guangdong, China) based on the Broad Institute's Segseq algorithm (Chiang et al., 2009) . Segseq can detect breakpoints at any read position. The segments were iteratively joined by eliminating the breakpoints. Statistical significance was calculated based on the number of reads in the tumor and normal samples in the entire segment. This enables a more accurate estimation of statistical significance because of the increased number of aligned reads (Chiang et al., 2009 ). We then used ANNOVAR to annotate the variant results (Wang, Li, & Hakonarson, 2010) , based on which subsequent advanced analysis could be conducted. Quality control (QC) was performed at each stage of the analysis pipeline.
3 | RESULTS
| Basic characteristics of the study participants
The basic characteristics of the 11 study participants are presented in Table 1 . Six of the participants had sporadic HB, and five had familial HB. Of the participants with familial HB, patient 21 and 23 came from the same family while patient 24 and 25 were from a different family.
Four of the patients were female (three had sporadic HB and one had familial HB), and the HBs appeared in different locations.
| Single nucleotide variation
We identified a total of 270 somatic single nucleotide variation (SNV) mutations in the 11 tumors, of which 67 (26.8%) might affect protein coding (61 missense, five nonsense, and one splice site; Table 2 ). These 270 somatic mutations are in 219 genes, with four genes (MAP4K3, NBPF20, PGM5, and ZNF814) having two mutations and 47 mutations located in intergenic regions. We found that, for most of the patients in this study, C: G>T: A transitions were the most common mutation in individual HB samples; however, the T: A>C: G mutation were also very common in many HB patients (Figure 1a ). In the VHL HBs, we did not identify any network that was found to be statistically significant after correction for multiple comparisons using the false discovery rate. We identified five genes, OTOGL, PLCB4, SCEL, THSD4, and WWOX, which has CNVs in the six patients with sporadic HB (Table 3) .
We identified three genes, ABCA6, CWC27, and LAMA2, with CNVs in the five patients with familial HBs (Table 4) .
| DISCUSSION
In this study, we performed whole exome sequencing (WES) on six patients with sporadic HBs and five patients with familial HBs to explore the potential genetic variations that may contribute to the tumorigenesis of HBs. We identified many mutations, the majority of which represent novel mutations, in both sporadic HBs and familial
HBs. We found a large number of CNVs in many patients with sporadic
HBs, but fewer CNVs in patients with familial HBs. To the best of our knowledge, this is the first WES study to examine potential genetic variations for HBs.
Nowadays, WES has become a very powerful strategy in the discovery of rare causal variants of inherited diseases and in the identification of additional somatic genetic variations that may account for unexplained heritability (Cirulli & Goldstein, 2010) . In this study, we screened and identified a number of potential new mutations in patients with HBs. For example, in patients with familial HBs, we found mutations in ZNF814, DLG2, RIMS1, PNN, and MUC7. Further studies CNVs are considered to be a significant source of genetic diversity, and they can influence phenotypic variability, such as disease susceptibility (Diskin et al., 2009 CNV, copy number variation. (Aqeilan & Croce, 2007; Salah, Aqeilan, & Huebner, 2010) . It exerts its cancer-suppressing function by suppressing the carcinogenic effects of oncogenes (Gaudio et al., 2006) , and/or by inducing cell apoptosis via activation of other tumor suppressor genes (Aqeilan et al., 2004) .
WWOX loses its expression in various tumors (Lewandowska et al., 2009 ). Previous studies have reported that the CNVs in WWOX are associated with increased risk of lung cancer and gliomas in a Chinese population (Yang et al., 2013; Yu et al., 2014) . We found that there were five common CNVs in WWOX (http://dgv.tcag.ca/dgv/app/ home?ref=GRCh37/hg19), none of which were among the list of CNVs that we identified in patients with sporadic HBs. Therefore, the CNVs we found in this study represent novel CNVs in WWOX that might be involved in the function of WWOX with respect to its role in cancer suppression and HB-tumorigenesis for sporadic HBs. Importantly, because the CNVs we identified in WWOX did not occur in the matched peripheral blood DNA, the occurrence of CNVs in WWOX within sporadic HBs might be due to acquired environment influences.
Future studies are needed to explore the potential mechanism of the identified CNVs in influencing the function of WWOX.
A recent study identified a reverse relationship between CNVs and mutations in 12 types of cancer such as glioblastoma multiformae and head and neck squamous cell carcinoma, and it found that tumors can roughly be divided into two classes based on somatic genetic variations: the M class predominantly has mutations while the C class predominantly has CNVs (Ciriello et al., 2013) . Overall all, we found a large number of CNVs (mean = 4345) but a relatively smaller number of mutations (mean = 14) in patients with sporadic HBs; in contrast, we found significantly fewer CNVs (mean = 1,600) but relatively more mutations (mean = 37) in familial HBs. However, we did not observe this inverse relationship in some of the individual patients. For example, we identified a large number of CNVs in patient 13 who had sporadic HB (n = 13,310), but he had an average number of SNVs (n = 14). Another sporadic HB patient (patient 16) had the least number of CNVs (n = 707), but an average number of SNVs (n = 13). These results highlight the genetic heterogeneity underlying the tumorigenesis of HB.
We identified several mutations/CNVs in genes that are involved in angiogenesis, such as vascular endothelial growth factor A (VEGFA) and VEGFC. VEGFA, located at 6p12, is a member of the cysteine knot family of growth factors, and it is produced by most cells in the body (Ferrara, 2004) . It is well known for its essential role in the growth of blood vessels and for its involvement in angiogenesis in brain tumors (Jain et al., 2007) . A recent study also reported that VEGFA was over-expressed in HB tissues in comparison to normal surrounding tissues from the same patients (Kruizinga et al., 2016) . We also observed many mutations/CNVs in the intergrin (ITG) gene family, such as ITGA8, ITGA1, ITGB5, and ITGB8. ITGB8, located on the cytogenetic band 7p21.1 of the human chromosome 1, can prevent neuronal apoptosis that is induced by deprivation of oxygen-glucose, and inhibition of ITGB8 leads to down regulation of VEGF (Zhang et al., 2012) . ITGB8 is also involved in the management of neurovascular physiology. Its removal in perivascular cells leads to the inability to regulate the active phases of blood vessel growth, leading to problems with neurovascular homeostasis (Salajegheh, 2016) . Suppression of ITGB8 can promote tumor growth and angiogenesis (Fang et al., 2011) . Many of the other genes that we identified in the ITG family also play important functions regarding angiogenesis or the pathogenesis of various types of tumors (Salajegheh, 2016) . These findings suggest potential pharmacological targets for the prevention and/or treatment of HBs.
Our study has some limitations. First, the sample size is rather limited. This prevented us from differentiating driver mutations from passenger mutations (Tokheim, Papadopoulos, Kinzler, Vogelstein, & Karchin, 2016) . More studies with larger sample sizes are needed to validate our findings. Second, the patients in this study were from a single hospital in China, and it is uncertain as to whether our findings can be generalized to patients of different races/ethnicities. Third, although we identified many genetic variations that might contribute to the tumorigenesis of HBs, in this exploratory analysis, we did not examine the underlying mechanisms. Future studies are also needed to investigate how multiple genetic variants interact with each other in the development of HBs. Finally, in this study, we used VarScan to detect the SNVs. Previous research indicated that this caller had a sensitivity >70% in whole-exome sequencing (Kroigard, Thomassen, Laenkholm, Kruse, & Larsen, 2016) , and had medium specificities (Cai, Yuan, Zhang, He, & Chou, 2016) . In summary, we performed WES in six patients with sporadic HBs and five patients with familial HBs. We found many SNVs and CNVs, many of which were reported to play essential roles in angiogenesis or the pathogenesis of cancers. Our findings highlight the complexity of the pathogenesis of HBs, even in patients with familial HBs. Future studies exploring the underlying mechanisms will further illustrate how multiple genetic variations lead to the initiation and progression of HB, and they can help pinpoint therapeutic targets for the treatment of HBs.
